These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32486990)

  • 21. Effectiveness of adjunctive, personalised psychosocial intervention for non-response to opioid agonist treatment: Study protocol for a pragmatic randomised controlled trial.
    Marsden J; Stillwell G; Hellier J; Brown AM; Byford S; Kelleher M; Kelly J; Murphy C; Shearer J; Mitcheson L
    Contemp Clin Trials; 2017 Feb; 53():36-43. PubMed ID: 27940188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methadone and buprenorphine-related deaths among people prescribed and not prescribed Opioid Agonist Therapy during the COVID-19 pandemic in England.
    Aldabergenov D; Reynolds L; Scott J; Kelleher MJ; Strang J; Copeland CS; Kalk NJ
    Int J Drug Policy; 2022 Dec; 110():103877. PubMed ID: 36265326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flexible delivery of opioid agonist treatment during COVID-19 in Norway: qualitative and quantitative findings from an online survey of provider experiences.
    McDonald R; Bech AB; Clausen T
    BMC Health Serv Res; 2023 Sep; 23(1):965. PubMed ID: 37679751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine.
    Meteliuk A; Galvez de Leon SJ; Madden LM; Pykalo I; Fomenko T; Filippovych M; Farnum SO; Dvoryak S; Islam ZM; Altice FL
    J Subst Abuse Treat; 2021 Feb; 121():108164. PubMed ID: 33191004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the Temporality Between Transitions onto Opioid Agonist Therapy and Engagement with Antiretroviral Therapy in a Cohort of HIV-Positive People Who Use Opioids Daily.
    Mitra S; Grant C; Nolan S; Mohd Salleh NA; Milloy MJ; Richardson L
    AIDS Behav; 2022 Jun; 26(6):1933-1942. PubMed ID: 34977956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
    Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
    Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interim opioid agonist treatment for opioid addiction: a systematic review.
    Samsó Jofra L; Puig T; Solà I; Trujols J
    Harm Reduct J; 2022 Jan; 19(1):7. PubMed ID: 35090475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
    Soyka M; Hillemacher T
    Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
    [No Abstract]   [Full Text] [Related]  

  • 29. Nasal Opioid Agonist Treatment in Patients with Severe Opioid Dependence: A Case Series.
    Vogel M; Köck P; Strasser J; Kalbermatten C; Binder H; Dürsteler KM; Walter M; Falcato L; Krausz M; Kormann A
    Eur Addict Res; 2022; 28(1):80-86. PubMed ID: 34311466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.
    Garg R; Kitchen SA; Men S; Campbell TJ; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Drug Alcohol Depend; 2022 Jul; 236():109459. PubMed ID: 35489179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients.
    Zahra E; Chen R; Nielsen S; Tran AD; Santo T; Degenhardt L; Farrell M; Byrne J; Ali R; Larance B
    Drug Alcohol Rev; 2022 May; 41(4):841-850. PubMed ID: 35130368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia.
    Jones NR; Shanahan M; Dobbins T; Degenhardt L; Montebello M; Gisev N; Larney S
    Drug Alcohol Rev; 2019 Sep; 38(6):690-698. PubMed ID: 31577058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analgesic management of acute pain in patients receiving methadone or buprenorphine].
    Zinck L; Sonne NM; Madsen SL; Nikolajsen L
    Ugeskr Laeger; 2015 Mar; 177(10):. PubMed ID: 25749118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland.
    Van Hout MC; Crowley D; McBride A; Delargy I
    BMC Fam Pract; 2018 Jun; 19(1):103. PubMed ID: 29960593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions.
    Tran AD; Chen R; Nielsen S; Zahra E; Degenhardt L; Santo T; Farrell M; Larance B
    Int J Drug Policy; 2022 Jan; 99():103472. PubMed ID: 34649203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
    Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
    Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Informing youth-centred opioid agonist treatment: Findings from a retrospective chart review of youths' characteristics and patterns of opioid agonist treatment engagement in a novel integrated youth services program.
    McInerney K; Marchand K; Buckley J; Gao C; Kestler A; Mathias S; Argyle A; Barbic S
    Early Interv Psychiatry; 2023 Oct; 17(10):1028-1037. PubMed ID: 37259685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opioid dependence - management in general practice.
    Frei M
    Aust Fam Physician; 2010 Aug; 39(8):548-52. PubMed ID: 20877747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using administrative data to predict cessation risk and identify novel predictors among new entrants to opioid agonist treatment.
    Bharat C; Degenhardt L; Dobbins T; Larney S; Farrell M; Barbieri S
    Drug Alcohol Depend; 2021 Nov; 228():109091. PubMed ID: 34592705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine.
    Morozova O; Dvoriak S; Pykalo I; Altice FL
    Drug Alcohol Depend; 2017 Apr; 173():132-138. PubMed ID: 28242537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.